MAR-RANOLAZINE XR DIN 02562448
Health Canada record
| Active ingredient(s) | RANOLAZINE 500 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C01EB18 RANOLAZINE |
| Original market date | 06-May-2026 |
| Current status date | 06-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Marcan Pharmaceuticals Inc. — licence 101909, currently licensed, last inspection rating C (2024-05-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RANOLAZINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02510219 | CORZYNA | KYE PHARMACEUTICALS INC. | Tablet (Extended-Release) | RANOLAZINE 500 MG | Marketed |
| 02510227 | CORZYNA | KYE PHARMACEUTICALS INC. | Tablet (Extended-Release) | RANOLAZINE 1000 MG | Marketed |
| 02558947 | CORZYNA | KYE PHARMACEUTICALS INC. | Tablet (Extended-Release) | RANOLAZINE 375 MG | Approved |
| 02558955 | CORZYNA | KYE PHARMACEUTICALS INC. | Tablet (Extended-Release) | RANOLAZINE 750 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36292 | 2025-10-29 | Abbreviated New Drug Submission (ANDS) |
International API supply for RANOLAZINE
24 active FDA Drug Master Files.
Request a quote for MAR-RANOLAZINE XR